Shilpa Medicare Ltd
Dr. Jayant Karajgi is a pharmacist by education and training. He holds Master’s and Doctorate degrees in Pharmaceutical Technology and is a University Gold Medallist for Bachelor’s and Master’s degrees.
He comes to Shilpa with 27 years of experience in generic pharmaceutical industry out of which last 13 years have been at leadership level as a techno-commercial professional, leading his teams to achieve business goals. His experience spans across all types of finished dosage forms and related operational aspects like product development, analytical and quality control laboratory, compliance, technology transfer, manufacturing, regulatory, customer management and supply chain. He has many international publications and patents to his credit and is an invited speaker across industry conferences and academic institutions.
He has developed and launched more than 400 products across various dosage forms for sale in US, EU, Japan and major ROW markets.
This person is not in any offices
Shilpa Medicare Ltd
Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation. The Company's segments include Bulk Drug/Intermediates and Energy. It offers 3a 7b Dihydroxy. The Company deals with APIs, Intermediates, Formulations, New Drug Delivery Systems, Peptides/Biotech products and Specialty Chemicals. The Company supplies oncology/non-oncology APIs and intermediates. Its oncology API products include Anastrozole, Axitinib, Azacitidine, Abiraterone Acetate, Bicalutamide, Bortezomib, Busulphan, Cabazitaxel Amorphous, Capecitabine, Carboplatin, Cladribine, Clofarabine, Zoledronic acid, Vismodegib, Pemetrexed DiPotassium Nonahydrate, Cyclophosphamide Monohydrate and Cytarabine. It also offers AntiRetroVirals. Its non-oncology API products include Acebrophylline, Echothiophate, Nifedipine, Perfenidone, PrucaloprideSuccinate, Sildenafil Citrate, Ursodeoxycholic acid and Dimethyl Fumarate.